These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22038905)

  • 1. High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
    Flicker K; Ulz P; Höger H; Zeitlhofer P; Haas OA; Behmel A; Buchinger W; Scheuba C; Niederle B; Pfragner R; Speicher MR
    Int J Cancer; 2012 Jul; 131(2):E66-73. PubMed ID: 22038905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
    Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
    Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.
    Ye L; Santarpia L; Cote GJ; El-Naggar AK; Gagel RF
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4367-72. PubMed ID: 18765511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
    Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
    Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome.
    Ramone T; Romei C; Ciampi R; Casalini R; Valetto A; Bertini V; Raimondi F; Onoja A; Prete A; Matrone A; Gambale C; Piaggi P; Torregrossa L; Ugolini C; Elisei R
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
    Ciampi R; Romei C; Cosci B; Vivaldi A; Bottici V; Renzini G; Ugolini C; Tacito A; Basolo F; Pinchera A; Elisei R
    Mol Cell Endocrinol; 2012 Jan; 348(1):176-82. PubMed ID: 21867742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.
    Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH
    Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.